(March 4, 2024, 2:57 PM EST) -- WILMINGTON, Del. — That a drugmaker’s “unprecedented” argument that incentives altered by the Inflation Reduction Act’s drug price negotiation provision provide standing to challenge the law fails “should come as no surprise,” and because the company lacks a protected right in selling to the government, its due process claim falls as well, a federal judge in Delaware said March 1 in granting summary judgment to the government....